EGLN2

Across TCGA pan-cancer cohorts, EGLN2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EGLN2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher EGLN2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EGLN2 expression acts as an unfavorable survival marker, although some lineages such as OV and BLCA show a favorable association.

OV, PRAD, and UCEC are the cancer types where EGLN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	III,IV	1.000	0.151	.025	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	IV	0.503	0.215	.020	6	view →
LIHC	OS	Median	All	0.144	0.704	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EGLN2–OV (DFS)

Open the OV breakdown →